ncp cardiovascular disease
TRANSCRIPT
-
8/18/2019 NCP Cardiovascular Disease
1/14
SCIENTIFIC METHOD : NCP-INTERMONEV CLINIC
CARDIOVASCULAR DISEASE
Kelompok 1
Erika Nr!i"ri 1#$%&%'%%111%1'
-
8/18/2019 NCP Cardiovascular Disease
2/14
LEMBAR KESEDIAAN AKTIF
Saa a(2 6er"a()a "a(2a( )i6a+a* i(i "ela* 6erko("ri6/i ak"i! )alam me(2er,aka(
/")i ka// i("ermo(e4 kli(ik "e("a(2 MNT pa)a 7Car)io4a/8lar )i/ea/e9
Erika Nr!i"ri;
1#$%&%'%%111%1'
I()a* D+i,aa("i;
1#$%&%'%1111%%.
Dia* P/pa;
1#$%&%'%1111%1%
L* 0e)e Dia* er)*a/""i;
1#$%&%'%1111%1'
-
8/18/2019 NCP Cardiovascular Disease
3/14
FORM NUTRITIONAL CARE PROSES
Nama : T(< MM =e(i/ kelami( : Laki-laki
Umr : #1 "* Dia2(o/a Me)i/ : Coro(ar Ar"er Di/ea/e po/" /"emi a("erior
e!/i!; Hiper"e(/i
DATA DASAR IDENTIFIKASI
MASALAH
DIA0NOSA INTERVENSI RENCANA MONEV
A("ropome"ri
>> : 33?$k2
T> : 1&% 8m
>iokimia
Da"a la6 Nilai
(ormal
Ha/il
pemerik/aa(
A/< Ura" '?$-&?%
m2@)l
3?5 m2@)l
HDL '$ m2@)l 53 m2@)l
LDL B1'% m2@)l 1&5 m2@)lT0 B1$% m2@)l 5%1 m2@)l
Kole/"er
ol
B5%% m2@)l 5.m2@)l
IMT : '%?. o6e/e
"i(2ka" 5;
A/am ra" :
HDL :
LDL :
T0 :
Kole/"erol :
Teka(a( )ara* :
NI $
-
8/18/2019 NCP Cardiovascular Disease
4/14
Fi/ik Kli(i/
Pemerik/aa( Ha/il
KU >aik
Ke/a)ara( Compo/me("i/
Teka(a( )ara* 1%@1%% mmH2
Na)i 1%1@me(i"
RR 5@me(i"
S6,ek"i! Neri )a)a /e6ela*
kiri ;
Se/ak (a!a/ ;
RPD Hiper"e(/i
Die"arDa*l
-Maka(a( pokok : (a/i J'@*ari 5%% 2
-Lak *e+a(i : "elr J#-$@mi(22 $% 2? ika(
keri(2 )a( 6a/a* J5-' kali@mi(22 $% 2
- Lak (a6a"i : "empe J'@*ari '%-$% 2? "a*
J'@*ari '%-$% 2
-Sar : /ara( *i,a J5@*ari 5$-$% 2?Sara( ka8a(2-ka8a(2a( J5@mi(22 5% 2?
+or"el J5@mi(22 $% 2? "oma"
J5@mi(22 $% 2- >a* : pi/a(2 J1-5@mi(22 $% 2r? pepaa
J1-5@mi(22 1%% 2r? apel@,erk@pir J1-
5@mi(22 1$% 2r
- Seli(2a( : ro"i J5@mi(22 #%-3% 2?
2ore(2a( J1@*ari 5-' 6a*
"i(22i
Na)i : "a8*8ar)ia
RR : Ta8*p(ea
Neri )a)a/e6ela* kiri ;?
Se/ak (a!a/ ;
Die"ar
P : #3G ;
KH : 11# G ;
Lemak ,e(* : '.
G ;
Pa/ie( /ka
me(2o(/m/i
maka(a( "i(22i
pri(
U)a(2@kera(2@ke
pi"i(2 ;
Pa/ie( 2emar
me(2ko(/m/i
2ore(2a( )a(
maka(a(
ke6"*a( )a( ka)ar T0
5%1 m2@)l
NI $D 1
-
8/18/2019 NCP Cardiovascular Disease
5/14
Lai(-lai( : Te* ma(i/ 5@*ari? kopi '@*ari
Se,ak $ "a*( a(2 lal pa/ie( memiliki
ke6ia/aa( maka( k(i(2 "elr me("a*? Pa/ie(
"i)ak memiliki aler2i
Sekara(2
Re8all Peme(*a(
E : 13'%?& kkal E : .3?.G
P : ''? 2 P : #3G
L : #.?' 2 L : .$ G
KH: '1? 2 KH: 11# G
Lemak ,e(* : 1.?'' 2 Lemak ,e(* : '.G
Kole/"erol : 1$? 2 Kole/"erol : &3G
O6a"
Mi(i a/pi 13% m2
Clopi)e 1&$ m2
Cap"opril '5$ m2Sim4a/"a"i(
>i/8or
ISDN
Diaepam
6er/a("a( /m6er
lemak ,e(*;
Pa/ie( 2emar
me(2ko(/m/i
k(i(2 "elrme("a* /m6er
kole/"erol;
− Cap"opril
'5$ m2
me(e6a6ka
( per6a*a(
i()era pe(2e8ap?
me(e6a6ka
( pe(r(a(a/pa(
maka(?
pe(r(a(
>> )a(
)a( "eka(a( )ara*
1%@1%% mmH2
N> 1 5
-
8/18/2019 NCP Cardiovascular Disease
6/14
a("a2o(i/ 4i"
>
− Sim4a/"a"i(
)iim6a(2i
)e(2a(
maka(a( 6er/era"
"i(22i )a(
me(2*i()ari
,/ ,erk
− Diaepam
me(e6a6ka
( )e!i/ie(/i
4i"< D? 4i"< K?
4i"< >15?
!ola"?)e!i/ie(/i
M2? Ca )a( 6eri("erak/i
)e(2a(
ka!ei(
-
8/18/2019 NCP Cardiovascular Disease
7/14
PRESKRIPSI DIET
A< T,a(
- Meme(*i ke6"*a( e(er2i )a( a" 2ii pa/ie( /e8ara peroral /e/ai )e(2a( ke6"*a( pa/ie( a2ar "i)ak "er,a)i komplika/i le6i* la(,"
- Me(2o("rol pro!il lipi) pa/ie(
-Me(2o("rol "eka(a( )ara* pa/ie(
>< Pri(/ip
- Re()a* lemak
- Re()a* lemak ,e(*
- Re()a* kole/"erol
- Re()a* lemak "ra(/
- Re()a* 2aram
- Re()a* pri(
- Ti(22i /era"
C< Sara"
- E(er2i )i6erika( /e/ai )e(2a( ke6"*a( pa/ie( )e(2a( memper*i"(2ka( 6era" 6a)a( a),/"e)? "i(22i 6a)a(? mr? )a( !ak"or ak"i4i"a/
pa/ie( ai" /e6e/ar 5$5& kkal
- Pro"ei( )i6erika( 8kp 1$ G )ari "o"al e(er2i ai" /e6e/ar .#?& 2r@*r; ("k me(22a("i /el a"a ,ari(2a( a(2 r/ak )a( )e2e(era/i
- Lemak )i6erika( re()a* 5$G )ari "o"al e(er2i ai" /e6e/ar &%?1. 2r@*r; )e(2a( ri(8ia(
Lemak ,e(* B 1%G )ari "o"al lemak B &?1. 2r@*r;
Kole/"erol B 5%% m2@*ari
Tra(/ !a" B 'G ke6"*a( e(er2i B 3?#5 2r;
-
Kar6o*i)ra" )i6erika( /e6e/ar '&.?%$ 2r@*r %G )ari "o"al e(er2i;- Sera" mi(imal '% 2r ("k me(8e2a* ko(/"ipa/i
- Na"rim )i6erika( %%-3%% m2@*r ("k me(,a2a "eka(a( )ara* pa/ie(
- Vi"ami( A )i6erika( %% m82 /e6a2ai a("iok/i)a( ("k me(2a"a/i "i(22i(a ra)ikal 6e6a/ )alam "6*
- Vi"ami( C )i6erika( .% m2 /e6a2ai a("iok/i)a( ("k me(2a"a/i "i(22i(a ra)ikal 6e6a/ )alam "6*
- Vi"ami( E )i6erika( 1$ m2 /e6a2ai a("iok/i)a( ("k me(2a"a/i "i(22i(a ra)ikal 6e6a/ )alam "6*
-
8/18/2019 NCP Cardiovascular Disease
8/14
- >e("k maka(a( 6ia/a? )e(2a( kompo/i/i ' maka( "ama )a( ' /(a8k
- Por/i ke8il a2ar "i)ak memperpara* /e/ak (a!a/ )a( (eri )a)a
D< Ke6"*a( e(er2i )a( a" 2ii
>>I T>-1%%; .%G
&% .%G ' k2
>> a),/"e) A> I>; %?5$ I>
33?$ '; %?5$ '
.?' k2
TEE 1%3 1%?1 /ia; PA 1'?& >> a),/"e); #1 T>;
1%3 1%?1 #1; 1?15 1'?& .?'; #1 1?&; 5$5& kkal
KH %G; '&.?%$ 2r
P 1$G; .#?& 2r
L 5$G; &%?1. 2r
Lemak ,e(* B &?1. 2r
Kole/"erol B 5%% m2
Lemak "ra(/ B 3?#5 2r
Sera" '% 2r
Na %%-3%% m2
Vi" A %% m82
-
8/18/2019 NCP Cardiovascular Disease
9/14
Vi" C .% m2
Vi" E 1$ m2
Form Men
E(er2i : 5$5& k8al Lemak : &%?1.2r KH : '&.?%$ 2r Sera" : '% 2r
Pro"ei( : .#?& 2r Na : %%-3%% m2
-
8/18/2019 NCP Cardiovascular Disease
10/14
W!"# Men B!$!n M!"!n!n Ber!# %&'Ener&(
%")!*'
+ro#e(n
%&'
Lem!"
%&'
K,
%&'
Ser!#
%m&'
N!
%m&'
V(#-A
%m)&'
V(#- .
%m&'
V(#- E
%m&'
-
8/18/2019 NCP Cardiovascular Disease
11/14
S!r!/!n N!( /#($ Na/i 1%% 1&$ # % #% %?' % % % %
%0-0003-00' .!/ )!4 or"el '% &?& %?' %?1 1?# 1?1 13 #&5?5 5?1 %?1
Kem6a(2 kol 5$ ?' %?' %?1 1?# %? #?$ '?' 3 %
Sa+i p"i* '% #?$ %?& %?1 %? %? #?3 .%?. &?$ %?
>a6 8or( 5$ 1#?3 %?# %?5 '?$ %?# 5?' 1?3 %?3 %
P"i* "elr '% 1$ '?5 % %?' % #.
-
8/18/2019 NCP Cardiovascular Disease
12/14
S7#o#!* 89:3 22 3 10:6 :; 1;3:2 6;1:1 191:3 2:3
S(!n& N!( /#($ Na/i 1%% 1&$ # % #% %?' % % % %
%12-001;-00'S/ ("!n
m!
Ve&e#!7*e
#e!m e&&Telr aam % .'?1 &? ?# %?& % ?#
11# % 1?5
or"el 5$ ?$ %?5 %?1 1?5 %?. 1$ '.'?$ 1?3 %?1
Ta* 5% 1$?5 1? 1 %?# %?5 1?# % % %
=a2(2 5% 51? %?& %?' $ %? '?# 5? 1?5 %
Da( 6a+a(2 1% 5?1 %?1 %?1 %?$ %?5 %? .? %?& %?1
S !/( S/ /api 5%% 1'1?. ?# &?3 .? % 11% 11% 5 %
Sn!)" (!n& B!$ /o#on& Apel #% 5'? %?1 %?5 ?1 1?1 % 5 5?# %?#
%19-00' Ma(22a $% '5?$ %?' %?5 3?$ %?. 1 $ 51?$ %?$
=am6 $% 5$?$ %?# %?' $?. 5?& 1?$ '.?$ .5 %?$
A(22r '% 51?' %?5 %?1 #?& %?5 %? 1?5 1?5 %?5
Ke )7(# Tep(2 "eri2 #% 1#$? #?1 %?# '%?$ 1?1 %?3 % % %
0la pa/ir 1' $%?' % % 1' % %?1 % % %
Telr aam '% #?$ '?3 '?5 %?' % '&?5 $& % %?
-
8/18/2019 NCP Cardiovascular Disease
13/14
Cokla" 5% .$?# %?3 $?. 15?& % 5?5 %?# % %?5
S7#o#!* =3:; ;:2 ;;:1 192:3 3:3 266:= ;:; 129:1 9:6
M!*!m N!( /#($ Na/i 1%% 1&$ # % #% %?' % % % %
%1-;013-;0' Tm(#em/e !4r
Tempe $% ..?$ .?$ '?3 3?$ %?& ' %?$ % %?$
Ke8am6a* 5% 15?5 1?' %?& 1 %?1 1?# %?5 1? %
or"el 5$ ?$ %?5 %?1 1?5 %?. 1$ '.'?$ 1?3 %?1
>(8i/ 5$ 3?& %?$ %?1 5 %?3 %?3 1?3 5?$ %
Mi(ak $ #'?1 % $ % % % 5$% % %?5
A4!m
/!n&&!n&
mer!$
Aam $% 1#5?# 1'?# .?# % % '?$
1.?$ % %
0la mera* $ 13?$ % % #?& % 1?. % % %
Mi(ak $ #'?1 % $ % % % 5$% % %
-
8/18/2019 NCP Cardiovascular Disease
14/14
KEBUTU,AN 5$5& .#?& &%?1. '&.?%$ '%%%-
3%%
%% .% 1$
+ERSENTASE .$?& G .& G .3?5 G .3?' G &?' G &.?5 G '3' G '%5 G $&?' G